How can society regulate and afford CRISPR therapies?

Press/Media: Expert Comment

Description

To offer gene-editing therapies as ‘standard clinical care’ in the future, it is imperative to lay the groundwork for regulatory procedures and cost-limiting approaches today.

Interview  by Henri van de Vrugt.

 

Period29 Jul 2021

Media contributions

1

Media contributions

  • TitleHow can society regulate and afford CRISPR therapies?
    Degree of recognitionInternational
    Media name/outletCRISPR News Medicine
    Media typeWeb
    Country/TerritoryNetherlands
    Date29/07/2021
    Producer/AuthorHenri van de Vrugt
    PersonsMartina Cornel, Tessel Rigter
View all 1
View less